Ratings Johnson & Johnson Swiss Exchange

Equities

JNJ

US4781601046

Delayed Swiss Exchange Other stock markets 11:36:39 2023-03-01 am EST			5-day change	1st Jan Change
500 ^CHF	+194.12%		-.--%	-.--%

04:15pm	Trending : Johnson & Johnson Beats 2Q Sales Guidance	DJ
03:53pm	Johnson & Johnson Cuts Full-Year Earnings Outlook Following Second-Quarter Beat	MT

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company is in a robust financial situation considering its net cash and margin position.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's enterprise value to sales, at 4.15 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JOHNSON & JOHNSON	-.--%	363B	-
ELI LILLY AND COMPANY	+56.94%	848B	C+
NOVO NORDISK A/S	+31.59%	627B	B
MERCK & CO., INC.	+15.07%	318B	B-
ABBVIE INC.	+12.62%	299B	C+
ASTRAZENECA PLC	+15.08%	243B	B+
NOVARTIS AG	+16.78%	225B	B-
AMGEN INC.	+16.04%	179B	C+
PFIZER, INC.	+4.25%	167B	C+
SANOFI	+2.42%	125B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes